Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: 2 out of 5

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Results 1 - 9 of 9

Recs

0
Member Avatar oscillation (< 20) Submitted: 6/1/2015 1:40:33 AM : Outperform Start Price: $0.74 CYCC Score: +8.46

nev

Recs

0
Member Avatar UnstableEnabled (< 20) Submitted: 12/21/2013 3:30:17 AM : Outperform Start Price: $3.85 CYCC Score: -92.38

A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.

It's entirely possible that other p.p.s. accelerators like accelerated approval and a SPA agreement with the FDA involving sapacitabine in MDS will advance the stock as well.

Sorely depressed, any good new will cause the stock to surge upward.

Recs

0
Member Avatar toegar2000 (54.06) Submitted: 3/2/2013 10:25:20 AM : Outperform Start Price: $5.50 CYCC Score: -121.21

Looks good IMO

Recs

0
Member Avatar stainsolution (84.59) Submitted: 4/9/2012 9:52:19 AM : Outperform Start Price: $4.55 CYCC Score: -131.80

Small Cancer/Bio

Recs

0
Member Avatar RBuskey106 (65.76) Submitted: 3/21/2012 8:23:14 PM : Outperform Start Price: $4.40 CYCC Score: -128.42

Small cancer bio

Recs

0
Member Avatar nwarrior (< 20) Submitted: 7/27/2011 2:55:42 AM : Outperform Start Price: $8.26 CYCC Score: -145.52

This stock is poised to rise, already near it's 52 Week low. With a high insider net holding volume and low debt, this is an investment with great potential.

Recs

0
Member Avatar rwaddoups (< 20) Submitted: 1/3/2011 1:22:52 PM : Outperform Start Price: $10.50 CYCC Score: -153.88

yes

Recs

0
Member Avatar verbatum (< 20) Submitted: 10/5/2010 8:03:18 PM : Outperform Start Price: $11.34 CYCC Score: -170.22

Great Pipeline,Great PHASE II, Entering PHASE III, Shelf registered, Orphan Designation

Recs

0
Member Avatar imrhh (< 20) Submitted: 5/5/2007 11:23:19 PM : Underperform Start Price: $54.60 CYCC Score: +142.54

This is one of Zack's #1 rated stocks. I do not understand their reasoning for this though. The chart that came up on my computer showed this stock starting at around zero and then going on a very steady decline to at least minus 100%. Call me crazy, but I can't see much of a future in this stock unless it is bought by one of the bigger companies.

Results 1 - 9 of 9

Featured Broker Partners


Advertisement